Publisher
Ferrata Storti Foundation (Haematologica)
Reference10 articles.
1. Lawless S, Iacobelli S, Knelange NS. Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling. Haematologica. 2023; 108(4):1105-1114.
2. Cook M, Panchal A, Brock K. Reduced intensity stem cell transplantation followed by adjunctive lenalidomide is tolerable and safe and improves complete response rate in multiple myeloma: a UK NCRI phase 2 feasibility study (LenaRIC). Blood. 2017; 130(Suppl 1):3308.
3. LeBlanc R, Ahmad I, Terra R. Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study. Bone Marrow Transplant. 2022; 57(2):252-260.
4. Zeiser R, von Bubnoff N, Butler J. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020; 382(19):1800-1810.
5. Kaiser MF, Hall A, Walker K. Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): results of the UK Optimum/MUKnine trial. J Clin Oncol. 2021; 39(15 Suppl):8001.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献